Phio Pharmaceuticals Corp. – NASDAQ:PHIOW

Phio Pharmaceuticals Corp. stock price today

$0.023
Financial Health
0
1
2
3
4
5
6
7
8
9

Phio Pharmaceuticals Corp. stock price quarterly change

-80.00%
quarter

Phio Pharmaceuticals Corp. stock price yearly change

-94.65%
year

Phio Pharmaceuticals Corp. key metrics

Market Cap
 421.41K
Enterprise value
 N/A
P/E
 -0.02
EV/Sales
 N/A
EV/EBITDA
 1.59
Price/Sales
 N/A
Price/Book
 0.03
PEG ratio
 N/A
EPS
 -3.59
Revenue
 N/A
EBITDA
 -9.18M
Income
 -9.37M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Phio Pharmaceuticals Corp. stock price history

Phio Pharmaceuticals Corp. stock forecast

Phio Pharmaceuticals Corp. financial statements

Profit Margin

Phio Pharmaceuticals Corp. (NASDAQ:PHIOW): Profit margin
Jun 2023 0 -2.54M
Sep 2023 0 -2.78M
Dec 2023 30K -1.89M -6316.67%
Mar 2024 0 -2.15M
PHIOW income statement history

Quarterly Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIOW): Earnings per share (EPS)
2020-08-12 -0.64 -0.34
PHIOW earnings history

Debt to Assets

Phio Pharmaceuticals Corp. (NASDAQ:PHIOW): Debt to assets
Jun 2023 12296000 2.39M 19.45%
Sep 2023 9539000 2.32M 24.38%
Dec 2023 9364000 1.63M 17.45%
Mar 2024 6853000 1.24M 18.23%
PHIOW balance sheet history

Cash Flow

Phio Pharmaceuticals Corp. (NASDAQ:PHIOW): Cash Flow
Jun 2023 -2.77M -5K 5.04M
Sep 2023 -2.9M 0 0
Dec 2023 -2.37M 0 2.40M
Mar 2024 -2.01M 0 -4K
PHIOW cash flow history

Phio Pharmaceuticals Corp. alternative data

Phio Pharmaceuticals Corp.
Employees

Phio Pharmaceuticals Corp. (NASDAQ:PHIOW): Employee count
Aug 2023 10
Sep 2023 10
Oct 2023 10
Nov 2023 10
Dec 2023 10
Jan 2024 10
Feb 2024 10
Mar 2024 10
Apr 2024 10
May 2024 10
Jun 2024 10
Jul 2024 10

Phio Pharmaceuticals Corp. other data

Phio Pharmaceuticals Corp.
Insider Trading

Phio Pharmaceuticals Corp. (NASDAQ:PHIOW): Insider trades (number of shares)
Period Buy Sel
Mar 2021 5135 0
Aug 2021 6000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
DISPERSYN GERRIT
Common stock, $0.0001 par value 6,000 $1.63 $9,780
Purchase
DISPERSYN GERRIT
Common stock, $0.0001 par value 1,953 $2.56 $5,000
Purchase
DISPERSYN GERRIT
Common stock, $0.0001 par value 2,500 $3.03 $7,575
Purchase
FERRARA ROBERT L
Common stock, $0.0001 par value 682 $3.15 $2,148
Purchase
DISPERSYN GERRIT
Common stock, $0.0001 par value 2,000 $2.5 $5,000
Purchase
CAUWENBERGH GEERT
Common stock, $0.0001 par value 10,000 $0.45 $4,500
Sale
ELISEEV ALEXEY
Common stock, par value $0.0001 58,712 $0.53 $31,000
Sale
ELISEEV ALEXEY
Common stock, par value $0.0001 91,907 $0.54 $49,354
Sale
ELISEEV ALEXEY
Common stock, par value $0.0001 26,181 $0.56 $14,583
Sale
ELISEEV ALEXEY
Common stock, $0.0001 par value 23,200 $0.57 $13,178
PHIOW insider trading transactions

Phio Pharmaceuticals Corp.
Executives

Insider Compensation
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D. (1975) Pres, Chief Executive Officer & Director
 $583,140

Frequently Asked Questions (FAQ)

  • What's the price of Phio Pharmaceuticals Corp. stock today?

    One share of Phio Pharmaceuticals Corp. stock can currently be purchased for approximately $0.02.

  • When is Phio Pharmaceuticals Corp.'s next earnings date?

    Unfortunately, Phio Pharmaceuticals Corp.'s (PHIOW) next earnings date is currently unknown.

  • Does Phio Pharmaceuticals Corp. pay dividends?

    No, Phio Pharmaceuticals Corp. does not pay dividends.

  • How much money does Phio Pharmaceuticals Corp. make?

    Phio Pharmaceuticals Corp. has a market capitalization of 421.41K. Phio Pharmaceuticals Corp. made a loss 10.83M US dollars in net income (profit) last year or -$0.34 on an earnings per share basis.

  • What is Phio Pharmaceuticals Corp.'s stock symbol?

    Phio Pharmaceuticals Corp. is traded on the NASDAQ under the ticker symbol "PHIOW".

  • What is Phio Pharmaceuticals Corp.'s primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Phio Pharmaceuticals Corp.?

    Shares of Phio Pharmaceuticals Corp. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Phio Pharmaceuticals Corp.'s key executives?

    Phio Pharmaceuticals Corp.'s management team includes the following people:

    • Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D. Pres, Chief Executive Officer & Director(age: 50, pay: $583,140)

  • How many employees does Phio Pharmaceuticals Corp. have?

    As Jul 2024, Phio Pharmaceuticals Corp. employs 10 workers.

  • When Phio Pharmaceuticals Corp. went public?

    Phio Pharmaceuticals Corp. is publicly traded company for more then 3 years since IPO on 31 Jan 2022.

  • What is Phio Pharmaceuticals Corp.'s official website?

    The official website for Phio Pharmaceuticals Corp. is phiopharma.com.

  • Where are Phio Pharmaceuticals Corp.'s headquarters?

    Phio Pharmaceuticals Corp. is headquartered at 257 Simarano Drive, Marlborough, MA.

  • How can i contact Phio Pharmaceuticals Corp.?

    Phio Pharmaceuticals Corp.'s mailing address is 257 Simarano Drive, Marlborough, MA and company can be reached via phone at +508 7673861.

Phio Pharmaceuticals Corp. company profile:

Phio Pharmaceuticals Corp.

phiopharma.com
Exchange:

NASDAQ

Full time employees:

10

Industry:

Biotechnology

Sector:

Healthcare

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

+508 7673861
257 Simarano Drive
Marlborough, MA 01752

CIK: 0001533040
:
: